News >

Frontline Bendamustine/Rituximab in MCL Improves Real-World EFS Outcomes

Wayne Kuznar
Published: Thursday, Dec 20, 2018

The frontline induction treatment of bendamustine and rituximab (Rituxan; BR) has improved event-free survival (EFS) compared with R-CHOP therapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) in patients with mantle cell lymphoma (MCL), according to an analysis of real-world data presented at the 2018 ASH Annual Meeting. 

“While patterns of care in MCL continue to evolve, the introduction of bendamustine and high-dose cytarabine-based regimens resulted in an improvement in EFS but not OS in this observational cohort-based analysis,” the investigators concluded.
Castellino A, Larson MC, Maurer MJ, et al. Patterns of care and outcomes in mantle cell lymphoma in the modern immunochemotherapy era. Presented at: 2018 ASH Annual Meeting; December 1-4, 2018; San Diego, California. Abstract 4140.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x